End: Wednesday, September 4, 2024 - 04:00 pm Categories:
North Dakota Medicaid Drug Use Review Board
Wednesday, Sept. 4, 2024
1:00 - 4:00 p.m. CT
In-Person Information
Conference Room 210/212, 2nd Floor, Judicial Wing, State Capitol
600 E. Boulevard Ave., Bismarck, ND 58505
Virtual Information
Join by computer: Click here to join the meeting
Join by phone: 701-328-0950, conference ID # 506 213 519
Agenda
- Call to Order
- Roll Call
- Review and Approval of Minutes
- Reports from Department
- Administrative Report
- Financial Report: Top Drugs
- Retrospective DUR Report
- Clinical Report:
- Prior Authorization Update
- Criteria updates: asthma/COPD, chronic kidney disease, Duchenne muscular dystrophy, growth hormone, heart failure, hereditary angioedema, hypertrophic cardiomyopathy, lipid-lowering treatment, plaque psoriasis, medications over $3000, dry eye disease
- Unfinished Business
- New Business
- Second Review of Molluscum Contagiosum (Ycanth and Zelsuvmi)
- Second Review of Epidermolysis Bullosa (Filsuvez)
- Second Review of Metabolic Dysfunction–Associated Steatohepatitis (Rezdiffra)
- First Review of Attention-Deficit Hyperactivity Disorder Stimulants
- Review of retrospective DUR criteria recommendations
- Announcements: Next Meeting (December 4, 2024)
- Adjourn
Individuals who need accommodations in order to participate or who would like information about joining the meeting can contact Ashley Gerving at 701-328-2354, 711 (TTY) or gervingashley@nd.gov.
Date Posted: January 18, 2024
Date Revised: August 22, 2024 (agenda/meeting details added)